InvestorsHub Logo
Followers 96
Posts 10066
Boards Moderated 1
Alias Born 06/11/2006

Re: RAND post# 431

Thursday, 01/11/2018 7:40:59 PM

Thursday, January 11, 2018 7:40:59 PM

Post# of 6197
The transaction maximizes the value of Aviragen: Based on the valuations of a selected set of publicly traded vaccine companies, Vaxart’s estimated potential valuation prior to the merger is approximately $158 million. Based on the ownership structure in the transaction, this would imply a value of the combined company at $264 million, with the potential value of Aviragen in the merger being $106 million, a significant improvement in value compared to Aviragen’s current market capitalization of approximately $23 million
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VXRT News